IceCure Medical Ltd.

Climate Impact & Sustainability Data (2023, January 2025)

Medium-term Goals:

Complete development of MultiSense system and obtain regulatory approval for commercialization.

Short-term Goals:

Obtain FDA approval for commercialization of products for treatment of malignant tumors in breast.

Limited operating history and significant operating losses since inception.
Minimal revenues from product sales.
Need to raise substantial additional funding.
Conditions raise substantial doubts about the Company’s ability to continue as a going concern.
Highly dependent on successful development, regulatory clearances, and marketing of ProSense, XSense, and MultiSense systems.
Dependence on third-party manufacturers and suppliers.
Small number of employees and key consultants.
Intense competition in the market.
Dependence on third-party payors for insurance coverage and reimbursement.
Limited experience managing a U.S. reporting company.
Vulnerability to security breaches and cybersecurity incidents.
Impact of changes in general economic conditions.
Political, economic, and military instability in Israel.
Enforcement of civil liabilities against the company and its officers may be difficult.

Expense reduction plan to reduce non-revenue generating and clinical efforts costs.
Plans to raise funds from existing shareholders and potential investors.
Continued investment in research and development.
Seeking additional distributors.
Monitoring inventory levels and maintaining recovery plans to address potential disruptions from suppliers.
Expanding commercial operations and entering new markets.
Efforts to obtain regulatory approvals for additional indications and in new jurisdictions.
Collaborating with key opinion leaders and medical associations.
Negotiating reimbursement with government and private insurers and payers.
Implementing security measures to prevent and minimize the impact of IT-related interruptions.

Climate Change Data